We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT01347671
Previous Study | Return to List | Next Study

Safety and Efficacy of GRT6005 in Pain Due to Diabetic Polyneuropathy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01347671
Recruitment Status : Completed
First Posted : May 4, 2011
Last Update Posted : July 15, 2021
Forest Laboratories
Information provided by (Responsible Party):
Tris Pharma, Inc.

Brief Summary:
The purpose of this trial is to investigate the efficacy and safety of GRT6005 in patients with painful diabetic neuropathy.

Condition or disease Intervention/treatment Phase
Pain Diabetic Neuropathies Drug: GRT6005 Drug: Matching Placebo Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 189 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized 4-week Phase IIa Trial Evaluating the Efficacy, Safety, and Tolerability of GRT6005, a New Centrally Acting Analgesic, in Subjects With Pain Due to Diabetic Polyneuropathy.
Study Start Date : May 2011
Actual Primary Completion Date : January 2012
Actual Study Completion Date : January 2012

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: 25 µg GRT6005
Participants allocated to this treatment arm will receive a daily dose of 25 µg GRT6005 per day
Drug: GRT6005
25µg/day once daily

Active Comparator: 75 µg GRT6005
Participants allocated to this treatment arm will receive a daily dose of 75 µg GRT6005 per day
Drug: GRT6005
75 µg/day once daily

Active Comparator: 200 µg GRT6005
Participants allocated to this treatment arm will receive a daily dose of 200 µg GRT6005 per day
Drug: GRT6005
200 µg/day once daily

Placebo Comparator: Matching Placebo
Participants allocated to this treatment arm will receive a dose of matched placebo once a day.
Drug: Matching Placebo
Once daily

Primary Outcome Measures :
  1. Change in mean daily pain intensity score [ Time Frame: Baseline to Week 4 ]

    Participants will be selected based on their medical history and clinical examination.

    Efficacy of the treatment (i.e., reduction of pain) will be evaluated with the 11-point numeric rating scale (NRS), where 0 represents no pain and 10 represents "pain as bad as you can imagine".

Secondary Outcome Measures :
  1. Response measured in percentage change of pain intensity from baseline [ Time Frame: End of 4 Weeks ]
  2. Changes in Quantitative Sensory Testing from baseline [ Time Frame: Baseline, week 1 and week 4 ]
  3. Neuropathic Pain Scale, changes from baseline [ Time Frame: End of 4 weeks ]
  4. Short Form of the Brief Pain Inventory, changes from baseline [ Time Frame: End of 4 weeks ]
  5. Leeds Sleep Evaluation Questionnaire [ Time Frame: End of treatment ]
  6. Quality of Life Index -Short-Form-12®, from baseline [ Time Frame: End of treatment ]
  7. Patient's Global Impression of Change [ Time Frame: End of treatment ]
  8. Quality of Life EuroQoL-5 Dimension score, change from baseline [ Time Frame: End of 4 weeks ]
  9. Rescue medication use [ Time Frame: End of 4 weeks ]
  10. Clinical Opioid Withdrawal Scale [ Time Frame: End of 4 weeks ]
  11. Plasma concentration [ Time Frame: End of 4 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Men and women, 18 to 75 years old.
  • Type 1 or type 2 diabetes.
  • Painful DPN symptoms and signs for at least 3 months.
  • Blood glucose controlled with medication.
  • Glycosylated hemoglobin not greater than 9.5 or 11%, country dependent.
  • Prior analgesic medication.
  • Average score of 4 or greater on the 11 point NRS during the last 3 days prior to randomization.

Exclusion Criteria:

  • Impaired liver, cardiac or renal function.
  • Breastfeeding and pregnancy.
  • History of substance abuse, alcohol or medication.
  • Chronic gastrointestinal disease.
  • History of seizures and or epilepsy.
  • History or presence of malignancy.
  • Presence of painful medical conditions that are not due to diabetic neuropathy, e.g. rheumatoid arthritis.
  • Allergies to opioids, acetaminophen or excipients of the medications.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01347671

Show Show 22 study locations
Sponsors and Collaborators
Tris Pharma, Inc.
Forest Laboratories
Layout table for investigator information
Principal Investigator: Thomas Forst, Prof. Dr. ikfe GmbH, Institut for Klinische Forschung und Entwicklung, Parcusstr. 8, 55116 Mainz, Germany
Layout table for additonal information
Responsible Party: Tris Pharma, Inc.
ClinicalTrials.gov Identifier: NCT01347671    
Other Study ID Numbers: 430409
2010-022557-42 ( EudraCT Number )
First Posted: May 4, 2011    Key Record Dates
Last Update Posted: July 15, 2021
Last Verified: July 2021
Keywords provided by Tris Pharma, Inc.:
chronic pain
neuropathic pain
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetic Neuropathies
Peripheral Nervous System Diseases
Neuromuscular Diseases
Nervous System Diseases
Diabetes Complications
Diabetes Mellitus
Endocrine System Diseases